Biotech's Patent Suite Catches Sparks From Federal Circuit's Prometheus Decision

Pharmaceutical and biotech firms will have broader patent protection after an appeals court drew a narrow definition of what constitutes a natural phenomenon in the biotech arena. Specifically, the court ruled that a test to measure a drug's metabolites in order to determine the proper drug dosage is patentable subject matter